The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
Open accessAbstract
Targeted delivery and controlled release of inactive platinum (Pt) prodrugs may offer a new approach to improve the efficacy and tolerability of the Pt family of drugs, which are used to treat 50% of all cancers today. Using prostate cancer (PCa) as a model disease, we previously described the engineering of aptamer (Apt)-targeted poly(D,L-lactic- co -glycolic acid)- b -poly(ethylene glycol) (PLGA- b -PEG) nanoparticles (NPs) encapsulating a Pt(IV) prodrug c , t , c [Pt(NH 3 ) 2 -(O 2 CCH 2 CH 2 CH 2 CH 2 CH 3 ) 2 Cl 2 ] ( 1 ) (Pt-PLGA- b -PEG-Apt-NP), which target the extracellular domain of the prostate specific membrane antigen (PSMA), for enhanced in vitro cytotoxicity. Here we demonstrate enhanced in vivo pharmacokinetics (PK), biodistribution, tolerability, and efficacy of Pt-PLGA- b -PEG-Apt-NP (150±15 nm encapsulating ∼5% wt/wt Pt(IV) prodrug) when compared to cisplatin administered in its conventional form in normal Sprague Dawley rats, Swiss Albino mice, and the PSMA-expressing LNCaP subcutaneous xenograft mouse model of PCa, respectively. The 10-d maximum tolerated dose following a single i.v. injection of Pt-PLGA- b -PEG-NP in rats and mice was determined at 40 mg/kg and 5 mg/kg, respectively. PK studies with Pt-PLGA- b -PEG-NP revealed prolonged Pt persistence in systemic blood circulation and decreased accumulation of Pt in the kidneys, a major target site of cisplatin toxicity. Pt-PLGA- b -PEG-Apt-NPs further displayed the significant dose-sparing characteristics of the drug, with equivalent antitumor efficacy in LNCaP xenografts at 1/3 the dose of cisplatin administered in its conventional form (0.3 mg/kg vs. 1 mg/kg). When considering the simultaneous improvement in tolerability and efficacy, the Pt-PLGA- b -PEG-Apt NP provides a remarkable improvement in the drug therapeutic index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Self-citationFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Self-citationStructure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Self-citationBiodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Self-citationDhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Self-citationNanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Self-citationChang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers
Gu, F., Zhang, L., Teply, B. A., Mann, N., Wang, A., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711714105 · Cited by 715
Self-citationDhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Self-citationUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug‐Delivery Platform
Bagalkot, V., Farokhzad, O. C., Langer, R., & Jon, S. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602251 · Cited by 613
Self-citationLee, H. B., & Blaufox, M. D. (1985) · PubMed · Cited by 583
Kolishetti, N., Dhar, S., Valencia, P. M., Lin, L. Q., Karnik, R., Lippard, S. J., Langer, R., & Farokhzad, O. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011368107 · Cited by 565
Self-citationMolecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Fair, W. R., & Heston, W. D. W. (1993) · PubMed · Cited by 541
Avgoustakis, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00530-2 · Cited by 503
Molecular Assembly of an Aptamer–Drug Conjugate for Targeted Drug Delivery to Tumor Cells
Huang, Y., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., & Tan, W. (2009) · ChemBioChem · doi:10.1002/cbic.200800805 · Cited by 422
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Self-citationTargeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
Sajja, H., East, M., Mao, H., Wang, Y., Nie, S., & Yang, L. (2009) · Current Drug Discovery Technologies · doi:10.2174/157016309787581066 · Cited by 250
Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor Vasculature
Mukhopadhyay, S., Barnés, C. M., Haskel, A., Short, S. M., Barnes, K. R., & Lippard, S. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc070031k · Cited by 226
Self-citationKawakami, M., & Nakayama, J. (1997) · PubMed · Cited by 203
Murphy, G. P., Elgamal, A. A., Su, S. L., et al. (1998) · PubMed · Cited by 168
Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., & Holmes, E. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2259::aid-cncr5>3.0.co;2-t · Cited by 150
Human Pregnane X Receptor and Resistance to Chemotherapy in Prostate Cancer
Chen, Y., Tang, Y., Wang, M.-T., Zeng, S., & Nie, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4758 · Cited by 143
Mattheolabakis, G., Taoufik, E., Haralambous, S., Roberts, M. L., & Avgoustakis, K. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.011 · Cited by 98
Formulation/Preparation of Functionalized Nanoparticles for In Vivo Targeted Drug Delivery
Gu, F., Langer, R., & Farokhzad, O. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-483-4_37 · Cited by 56
Self-citationWang, S., Mi, J., Li, Y., et al. (2003) · PubMed · Cited by 11
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Self-citationNanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Metadata
- Authors
- Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-01-13
- Volume
- 108
- Issue
- 5
- Pages
- 1850-1855
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2011030869
- Cited by
- 513
- References
- 30
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.